US2013253180A1PendingUtilityA1

Antisense oligonucleotides for inducing exon skipping and methods of use thereof

Assignee: UNIV WESTERN AUSTRALIAPriority: Jun 28, 2004Filed: May 24, 2013Published: Sep 26, 2013
Est. expiryJun 28, 2024(expired)· nominal 20-yr term from priority
A61P 21/00C12N 2310/3233C12N 2310/3519C12N 2310/11C12N 2310/33C12N 2310/321C12N 15/113C12N 2320/30C12N 2310/315C12N 2320/33C12N 2310/3341
71
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Antisense molecules capable of binding to a selected target site in the dystrophin gene to induce exon skipping are described.

Claims

exact text as granted — not AI-modified
1 . (canceled) 
     
     
         2 . An isolated antisense oligonucleotide 20 to 50 nucleotides comprising at least 17 bases of the sequence CUG UUG CCU CCG GUU CUG AAG GUG (SEQ ID NO:192), or an equivalent oligonucleotide, wherein said oligonucleotide, or its equivalent, induces exon 53 skipping in the human dystrophin pre-mRNA, and wherein the oligonucleotide comprises a modification, said modification comprising a base substitution of U by T. 
     
     
         3 . An isolated antisense oligonucleotide of 24-50 nucleotides in length, said oligonucleotide comprising a sequence which is complementary to a target nucleic acid sequence of the human exon 53 pre-mRNA, wherein said target nucleic acid sequence comprises a 24 nucleotide sequence that is complementary to the sequence CUG UUG CCU CCG GUU CUG AAG GUG (SEQ ID NO:192), and wherein the oligonucleotide comprises a modification, said modification comprising a base substitution of U by T.

Join the waitlist — get patent alerts

Track US2013253180A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.